The Biotech Banter crew is getting into the World Cup spirit, looking at foreign biotechs to see whether they're investable.

First up:

Amarin (NASDAQ:AMRN) has a drug on the market, but unfortunately its fish oil Vascepa has struggled to gain much traction. The hope was that the company could get FDA approval for a wider population of patients with moderately high triglyceride levels, but the FDA shot down the idea.

Prosensa (NASDAQ:RNA) is developing a Duchenne muscular dystrophy drug called drisapersen. The drug failed a phase 3 trial, but the company thinks it might still be able to get the drug approved.

Jazz Pharmaceuticals (NASDAQ:JAZZ) is a specialty pharma focused on narcolepsy, oncology, pain, and psychiatry. Shares in the company are up about 125% over the past year, so it must be doing something right.

Watch the following video to see whether senior biotech specialist Brian Orelli and health-care analyst David Williamson give the companies a goal, raise a yellow card, or send them off with a red card.

Brian Orelli has no position in any of the stocks mentioned. David Williamson owns shares of Amarin. The Motley Fool recommends BMW and Nike and owns shares of Nike. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.